Zhao et al., 2025 - Google Patents
TAGLN2 exacerbates acute pancreatitis-induced liver injury by increasing hepatocyte pyroptosis via kupffer cells-mediated inflammatory responseZhao et al., 2025
View PDF- Document ID
- 7232663212163385764
- Author
- Zhao H
- Luo Y
- Chen X
- Wu J
- Zhu Z
- Chen H
- Publication year
- Publication venue
- Archivum immunologiae et therapiae experimentalis
External Links
Snippet
Pyroptosis, a pro grammed form of inflammatory cell death, has been demonstrated to participate in both Acute pancreatitis (AP) and its complication liver injury. Transgelin-2 (TAGLN2), an actin-binding protein involved in inflammatory response, has been reported to …
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Feng et al. | IL-17 induces myocardial fibrosis and enhances RANKL/OPG and MMP/TIMP signaling in isoproterenol-induced heart failure | |
| Li et al. | Triptolide ameliorates IL-10-deficient mice colitis by mechanisms involving suppression of IL-6/STAT3 signaling pathway and down-regulation of IL-17 | |
| Iwasaki et al. | Regulation of cellular senescence in type 2 diabetes mellitus: from mechanisms to clinical applications | |
| Liu et al. | Deubiquitinase USP18 regulates reactive astrogliosis by stabilizing SOX9 | |
| Chai et al. | NLRP3 blockade suppresses pro-inflammatory and pro-angiogenic cytokine secretion in diabetic retinopathy | |
| Song et al. | Inhibition of microRNA‐132 attenuates inflammatory response and detrusor fibrosis in rats with interstitial cystitis via the JAK‐STAT signaling pathway | |
| US20160354437A1 (en) | Compositions and methods for modulation of immune response | |
| CN112675165A (en) | Application of ellagic acid and metabolite thereof as natural inhibitor in preparation of anti-cell apoptosis drug | |
| Zhao et al. | TAGLN2 exacerbates acute pancreatitis-induced liver injury by increasing hepatocyte pyroptosis via kupffer cells-mediated inflammatory response | |
| Zhang et al. | IL‐17A‐neutralizing antibody ameliorates inflammation and fibrosis in rosacea by antagonizing the CXCL5/CXCR2 axis | |
| Xu et al. | Anti-rheumatoid arthritic effects of Saussurea involucrata on type II collagen-induced arthritis in rats | |
| Yuan et al. | Relaxin in fibrotic ligament diseases: Its regulatory role and mechanism | |
| Ha et al. | Enhancement of gastric ulcer healing and angiogenesis by hepatocyte growth factor gene mediated by attenuated salmonella in rats | |
| CN113372435A (en) | Polypeptide for promoting angiogenesis and pharmaceutical application thereof | |
| Liu et al. | Pro‐Atherosclerotic Effects of Osteopontin Is Contributed to Promoting Foam Cell Formation Derived From VSMCs by Inhibiting Cholesterol Efflux | |
| CN114113630B (en) | Application of SERPINB3/B4 as target spot in medicines for treating inflammatory skin diseases such as rosacea | |
| CN118121597A (en) | Application of STING inhibitor H-151 in preparation of medicine for treating non-alcoholic fatty liver disease | |
| KR20240044297A (en) | Application of a vegfr gene expression inhibitor as a formulation or formulation for the treatment of psoriasis | |
| CN114432302B (en) | Use of small molecule SR9009 in anti-aging and alleviating chronic inflammation caused by aging | |
| US8507446B2 (en) | Use of PEDF-derived polypeptides for treating liver cirrhosis | |
| US20200231689A1 (en) | Treatment of mood and stress related disorders | |
| Zhang et al. | Effect of AR gene-specific knockout on the process of radiation-induced pulmonary fibrosis and its mechanism | |
| JP2007534672A5 (en) | Treatment of type 1 diabetes using macrophage migration inhibitory factor inhibitor | |
| Wu et al. | Role of cytokines in the progression of hepatic fibrosis: A review. | |
| CN116196423B (en) | Application of chemokine CCL17 as a therapeutic target in the preparation of products that inhibit or delay aging |